Recomendaciones aprobadas en la Reunión Latinoamericana de Expertos Gubernamentales sobre Ciencia y Tecnología para el Desarrollo = Recommendations approved by the Latin American Meeting of Intergovernmental Experts on Science and Technology for Development

Extracto del informe de la Reunión, celebrada del 31 octubre al 2 noviembre 1977, para ser presentado a la Segunda Reunión del Comité Preparatorio para la Conferencia de las Naciones Unidas sobre Ciencia y Tecnología para el Desarrollo, Ginebra, 23 enero-3 febrero 1978

Latin American plan of action for the application of science and technology to development

Includes bibliography

Second Latin American meeting of bodies responsible for the supervision, control and regulation of land transport

This edition of the Bulletin presents a summary of topics examined and discussed during the Second Latin American Meeting of Bodies Responsible for the Supervision, Control and Regulation of Land Transport, held at ECLAC Headquarters, Santiago, Chile, from 10 to 12 August 1999. The rapporteur of the meeting was Mr. Humberto Valdés Ríos, Sub-Director, Asociación de Investigación y Producción del Transporte, Cuba.

Division of labor between M and P visual pathways: different visual pathways minimize joint entropy differently

Visual perception and action are strongly linked with parallel processing channels connecting the retina, the lateral geniculate nucleus, and the input layers of the primary visual cortex. Achromatic vision is provided by at least two of such channels formed by the M and P neurons. These cell pathways are similarly organized in primates having different lifestyles, including species that are diurnal, nocturnal, and which exhibit a variety of color vision phenotypes. We describe the M and P cell properties by 3D Gábor functions and their 3D Fourier transform. The M and P cells occupy different loci in the Gábor information diagram or Fourier Space. This separation allows the M and P pathways to transmit visual signals with distinct 6D joint entropy for space, spatial frequency, time, and temporal frequency. By combining the M and P impacts on the cortical neurons beyond V1 input layers, the cortical pathways are able to process aspects of visual stimuli with a better precision than it would be possible using the M or P pathway alone. This performance fulfils the requirements of different behavioral tasks.

Indigenous American species of the Bemisia tabaci complex are still widespread in the Americas

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

AAUW- Rock Hill Chapter Records (American Association of University Women) - Accession 13

The AAUW- Rock Hill Chapter Records consists of minutes, membership lists, correspondence, newspaper clippings, financial statements, constitutions and by-laws and branch reports of the chapter’s presidents and committee chairmen to the national office, extending from 1925 to 1985.

Taxonomy and Life Histories of Two North American Species of "Carneophallus" (=Microphallus) (Digenea: Microphallidae)

Discusses the taxonomy and life histories of two North American species of Carneophallus" (=Microphallus) (Digenea: Microphallidae).

Host-Specificity of Myxoma Virus: Pathogenesis of South American and North American Strains of Myxoma Virus in Two North American Lagomorph Species

The pathogenesis of South American and North American myxoma viruses was examined in two species of North American lagomorphs, Sylvilagus nuttallii (mountain cottontail) and Sylvilagus audubonii (desert cottontail) both of which have been shown to have the potential to transmit the South American type of myxoma virus. Following infection with the South American strain (Lausanne, Lu), S. nuttallii developed both a local lesion and secondary lesions on the skin. They did not develop the classical myxomatosis seen in European rabbits (Oryctolagus cuniculus). The infection at the inoculation site did not resolve during the 20-day time course of the trial and contained transmissible virus titres at all times. In contrast, S. audubonii infected with Lu had very few signs of disseminated infection and partially controlled virus replication at the inoculation site. The prototype Californian strain of myxoma virus (MSW) was able to replicate at the inoculation site of both species but did not induce clinical signs of a disseminated infection. In S. audubonii, there was a rapid response to MSW characterized by a massive T lymphocyte infiltration of the inoculation site by day 5. MSW did not reach transmissible titres at the inoculation site in either species. This might explain why the Californian myxoma virus has not expanded its host-range in North America.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9: 242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia.

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

Purpose To update American Society of Clinical Oncology/American Society of Hematology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. Methods An Update Committee reviewed data published between January 2007 and January 2010. MEDLINE and the Cochrane Library were searched. Results The literature search yielded one new individual patient data analysis and four literature-based meta-analyses, two systematic reviews, and 13 publications reporting new results from randomized controlled trials not included in prior or new reviews. Recommendations For patients undergoing myelosuppressive chemotherapy who have a hemoglobin (Hb) level less than 10 g/dL, the Update Committee recommends that clinicians discuss potential harms (eg, thromboembolism, shorter survival) and benefits (eg, decreased transfusions) of ESAs and compare these with potential harms (eg, serious infections, immune-mediated adverse reactions) and benefits (eg, rapid Hb improvement) of RBC transfusions. Individual preferences for assumed risk should contribute to shared decisions on managing chemotherapy-induced anemia. The Committee cautions against ESA use under other circumstances. If used, ESAs should be administered at the lowest dose possible and should increase Hb to the lowest concentration possible to avoid transfusions. Available evidence does not identify Hb levels � 10 g/dL either as thresholds for initiating treatment or as targets for ESA therapy. Starting doses and dose modifications after response or nonresponse should follow US Food and Drug Administration–approved labeling. ESAs should be discontinued after 6 to 8 weeks in nonresponders. ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes. Caution should be exercised when using ESAs with chemotherapeutic agents in diseases associated with increased risk of thromboembolic complications. Table 1 lists detailed recommendations. This guideline was developed through a collaboration between the American Society of Clinical Oncology and the American Society of Hematology and has been published jointly by invitation and consent in both Journal of Clinical Oncology and Blood.

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

Purpose: To update American Society of Hematology/American Society of Clinical Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. Methods: An Update Committee reviewed data published between January 2007 and January 2010. MEDLINE and the Cochrane Library were searched. Results: The literature search yielded one new individual patient data analysis and four literature-based meta-analyses, two systematic reviews, and 13 publications reporting new results from randomized controlled trials not included in prior or new reviews. Recommendations: For patients undergoing myelosuppressive chemotherapy who have a hemoglobin (Hb) level less than 10 g/dL, the Update Committee recommends that clinicians discuss potential harms (eg, thromboembolism, shorter survival) and benefits (eg, decreased transfusions) of ESAs and compare these with potential harms (eg, serious infections, immune-mediated adverse reactions) and benefits (eg, rapid Hb improvement) of RBC transfusions. Individual preferences for assumed risk should contribute to shared decisions on managing chemotherapy-induced anemia. The Committee cautions against ESA use under other circumstances. If used, ESAs should be administered at the lowest dose possible and should increase Hb to the lowest concentration possible to avoid transfusions. Available evidence does not identify Hb levels 10 g/dL either as thresholds for initiating treatment or as targets for ESA therapy. Starting doses and dose modifications after response or nonresponse should follow US Food and Drug Administration-approved labeling. ESAs should be discontinued after 6 to 8 weeks in nonresponders. ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes. Caution should be exercised when using ESAs with chemotherapeutic agents in diseases associated with increased risk of thromboembolic complications. Table 1 lists detailed recommendations.